Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’

Reappraisal of GIP Pharmacology for Metabolic Diseases

(2016) Brian Finan et al.   TRENDS IN MOLECULAR MEDICINE

Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances

(2016) Meena Asmar et al.   Current Opinion in Endocrinology Diabetes and Obesity

Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors

(2015) A H Sparre-Ulrich et al.   BRITISH JOURNAL OF PHARMACOLOGY

Peptide therapeutics: current status and future directions

(2015) Keld Fosgerau et al.   DRUG DISCOVERY TODAY

Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists

(2015) Brian Finan et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Liraglutide and obesity: a review of the data so far

(2015) Ellen Ladenheim   Drug Design Development and Therapy

Glucagon and Type 2 Diabetes: the Return of the Alpha Cell

(2014) Asger Lund et al.   Current Diabetes Reports

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities

(2014) Asger Lund et al.   European Journal of Internal Medicine

A Naturally Occurring GIP Receptor Variant Undergoes Enhanced Agonist-Induced Desensitization, Which Impairs GIP Control of Adipose Insulin Sensitivity

(2014) S. Mohammad et al.   MOLECULAR AND CELLULAR BIOLOGY

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes: Systematic review and meta-analysis of clinical studies

(2013) S. Calanna et al.   DIABETES CARE

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

(2013) S. Calanna et al.   DIABETOLOGIA

Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes

(2013) Mikkel B. Christensen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Emerging combinatorial hormone therapies for the treatment of obesity and T2DM

(2013) Sharon A. Sadry et al.   Nature Reviews Endocrinology

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity: The Case for Personalized Combinatorial Therapies

(2012) M. H. Tschop et al.   DIABETES

GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis

(2012) Su-Jin Kim et al.   PLoS One

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes

(2011) Asger Lund et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity

(2011) Victor A. Gault et al.   CLINICAL SCIENCE

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans

(2011) M. Christensen et al.   DIABETES

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes

(2011) N. Mentis et al.   DIABETES

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity

(2011) F. K. Knop et al.   DIABETES OBESITY & METABOLISM

Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice

(2011) Emilie Faivre et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans

(2010) M. Asmar et al.   DIABETES

The metabolic actions of glucagon revisited

(2010) Kirk M. Habegger et al.   Nature Reviews Endocrinology

The direct effects of GLP-1 and GIP, alone or in combination, on human pancreatic islets

(2010) R. Lupi et al.   REGULATORY PEPTIDES

Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes

(2009) C. Daousi et al.   CLINICAL ENDOCRINOLOGY

Exogenous Glucose-Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes

(2009) C. W. Chia et al.   DIABETES

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA

Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice

(2008) Nigel Irwin et al.   REGULATORY PEPTIDES